DABIGATREX 150

If you are breastfeeding, consult your doctor before using Dabigatran Etexilate. Information about its safety during breastfeeding is limited, so your healthcare professional should assess the potential risks to the infant and the benefits of treatment. Do not independently discontinue the medicine or change your feeding plan without professional guidance.

Dabigatran Etexilate does not usually directly affect the ability to drive. However, avoid driving if you experience dizziness, weakness, or symptoms that affect your concentration. Because this medicine increases bleeding risk, seek urgent medical attention after a significant accident or head injury, even if you initially feel well.

Dabigatran Etexilate is mainly eliminated through the kidneys. Reduced kidney function can cause the medicine to accumulate in the body, increasing the risk of serious bleeding. Inform your doctor if you have kidney disease before starting treatment. Your doctor may assess kidney function and determine whether dose adjustment or an alternative medicine is appropriate.

Tell your doctor about any existing liver disease before taking Dabigatran Etexilate. Liver problems may affect blood clotting and increase the risk of bleeding, depending on the condition and its severity. Your doctor will assess whether this medicine is suitable for you. Seek medical advice if you notice unusual bruising, persistent bleeding, or yellowing of the skin or eyes.